Last reviewed · How we verify
Ampicillin sulbactam 3 days
Ampicillin sulbactam 3 days is a Small molecule drug developed by Universitas Diponegoro. It is currently FDA-approved.
At a glance
| Generic name | Ampicillin sulbactam 3 days |
|---|---|
| Sponsor | Universitas Diponegoro |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Therapeutic Options for CRAB (PHASE4)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes (NA)
- TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden (PHASE3)
- Biomarkers & Infection After Prophylactic Antibiotic in Cardiac Implantable Electronic Device Implantation (PHASE4)
- Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
- Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ampicillin sulbactam 3 days CI brief — competitive landscape report
- Ampicillin sulbactam 3 days updates RSS · CI watch RSS
- Universitas Diponegoro portfolio CI
Frequently asked questions about Ampicillin sulbactam 3 days
What is Ampicillin sulbactam 3 days?
Ampicillin sulbactam 3 days is a Small molecule drug developed by Universitas Diponegoro.
Who makes Ampicillin sulbactam 3 days?
Ampicillin sulbactam 3 days is developed and marketed by Universitas Diponegoro (see full Universitas Diponegoro pipeline at /company/universitas-diponegoro).
What development phase is Ampicillin sulbactam 3 days in?
Ampicillin sulbactam 3 days is FDA-approved (marketed).
Related
- Manufacturer: Universitas Diponegoro — full pipeline
- Compare: Ampicillin sulbactam 3 days vs similar drugs
- Pricing: Ampicillin sulbactam 3 days cost, discount & access